Cerevel Therapeutics Holdings Inc. (NASDAQ: CERE) stock closed at 23.43 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 422.41K shares and market capitalization of 3.67B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 104 people. Cerevel Therapeutics Holdings Inc. CEO is N. Anthony Coles.

The one-year performance of Cerevel Therapeutics Holdings Inc. stock is -31.21%, while year-to-date (YTD) performance is -25.71%. CERE stock has a five-year performance of %. Its 52-week range is between 19.86 and 41.46, which gives CERE stock a 52-week price range ratio of 16.53%

Cerevel Therapeutics Holdings Inc. currently has a PE ratio of -14.40, a price-to-book (PB) ratio of 7.96, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -37.05%, a ROC of -39.39% and a ROE of -55.93%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Cerevel Therapeutics Holdings Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.67 for the next earnings report. Cerevel Therapeutics Holdings Inc.’s next earnings report date is 09th May 2023.

The consensus rating of Wall Street analysts for Cerevel Therapeutics Holdings Inc. is Moderate Buy (1.62), with a target price of $41.25, which is +76.06% compared to the current price. The earnings rating for Cerevel Therapeutics Holdings Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cerevel Therapeutics Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cerevel Therapeutics Holdings Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 53.60, ATR14 : 1.39, CCI20 : -101.70, Chaikin Money Flow : 0.03, MACD : -1.77, Money Flow Index : 34.57, ROC : -11.92, RSI : 34.49, STOCH (14,3) : 15.53, STOCH RSI : 0.80, UO : 44.69, Williams %R : -84.47), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cerevel Therapeutics Holdings Inc. in the last 12-months were: Abraham Ceesay (Option Excercise at a value of $1 265 058), Abraham Ceesay (Sold 96 056 shares of value $3 255 048 ), Deval L. Patrick (Option Excercise at a value of $602 037), Deval L. Patrick (Sold 47 705 shares of value $1 468 421 ), Gabrielle Sulzberger (Option Excercise at a value of $0), John Renger (Option Excercise at a value of $1 219 073), John Renger (Sold 241 105 shares of value $8 200 133 ), N. Anthony Coles (Option Excercise at a value of $700 000), N. Anthony Coles (Sold 200 000 shares of value $5 842 516 ), Scott Akamine (Option Excercise at a value of $131 700), Scott Akamine (Sold 10 000 shares of value $400 001 )